中国上海，2017年12月22日。中国创新型医药领军企业—华领医药今日宣布，在美国和亚洲地区具有丰富经验的投资银行家林洁诚先生正式加入华领医药，担任执行副总裁和首席财务官。
林洁诚先生在医疗健康行业拥有超过20年的投资银行以及法律事务工作经验，曾与全球多家私营企业和上市公司合作。加入华领医药之前，林先生近年在香港工作，担任美银美林亚太区消费品、零售及医疗保健领域的投资银行业务负责人，以及香港、台湾地区投资银行业务负责人。林先生曾负责在亚洲、美国和欧洲地区的众多知名企业IPO、债务重组、股权融资和并购业务。林先生在美国加州大学戴维斯分校获得生物科学学士学位，在芝加哥大学法学院获得法律博士学位。
作为华领医药执行副总裁和首席财务官，林先生的职责将包括公司财务、商务拓展和新产品的引进合作等方面业务，进一步扩展拥有III期临床阶段全球首创糖尿病新药的华领医药公司价值。
华领医药在2016年成功完成了其2型糖尿病首创新药“葡萄糖激酶正向别构调节剂(GKPAM)-Dorzagliatin(HMS5552)”的II期验证性临床研究，该研究在全国22家具有领先水平的临床中心开展，入组病人数是258位，(研究结果于2016年10月对外发布)。目前，华领医药已在国内启动NDA申报阶段的工作，2个III期临床研究正同时展开，其中包括由中华医学会糖尿病学分会候任主委朱大龙教授领衔的，针对2型糖尿病新发患者的Dorzagliatin单药研究，以及由中华医学会糖尿病学分会前任主委杨文英教授领衔的Dorzagliatin和二甲双胍联合用药研究,全国共有80家临床中心参与了本次研究。
“我们非常高兴林洁诚先生能够领导华领的财务以及业务拓展工作，共同推进我们的糖尿病创新药开发，造福中国以及全球的糖尿病患者。”华领医药CEO陈力博士说：“据世界卫生组织统计，当今，糖尿病是一种全球性的发病率较高的疾病，在全球超过4.22亿的糖尿病患者中，仅中国就有1.2亿。中国2型糖尿病患病率，汉族人群为14.7％，穆斯林人群为10％；在美国，2型糖尿病患病率为9.4％。在一定程度上，造成2型糖尿病病程不断发展的主因是现有降糖药疗效的局限性以及葡萄糖传感器，GK受损的功能未被治疗。华领医药的“葡萄糖激酶正向别构调节剂(GK PAM)”已显示其修复2型糖尿病患者受损的GK功能、重塑血糖稳态平衡的潜力，是遏制2型糖尿病病程发展的一个新的治疗理念。
关于华领
华领医药是一家立足中国，针对全球糖尿病患者尚未满足的临床需求，研发全球原创新药的生物技术公司。华领医药汇聚全球高端人才和科技资源，以国际顶级生物医药投资团队为依托，成功实现了全球首创糖尿病新药Dorzagliatin（HMS5552）在中国完成药品可开发性临床验证，率先进入注册性临床试验阶段。公司已在中国开展2个III期临床试验，分别针对新发未经治疗的和二甲双胍治疗失效的2型糖尿病患者人群。公司将启动药品生命周期管理相关临床试验，并拓展糖尿病个性化治疗和管理的先进理念，联合中国和美国糖尿病领域专家，实现对糖尿病和代谢性疾病及其并发症的有效控制。更多信息：www.huamedicine.com。
Bank of America Merrill Lynch Investment Banking Veteran Joins Hua Medicine as CFO
Shanghai, China – December 22, 2017. Hua Medicine, a leading clinical stage biotechnology company based in Shanghai, announced George Lin, a seasoned investment banker in the U.S. and Asia, joins Hua Medicine as EVP and Chief Financial Officer.
Mr. George Lin, a healthcare veteran brings with him over 20 years of investment banking and legal experience working with numerous private and public companies globally. Prior to joining Hua, he was Asia Pacific Head of Consumer, Retail and Healthcare Investment Banking and head of investment banking coverage for both Hong Kong and Taiwan for Bank of America Merrill Lynch based in Hong Kong. As an investment banker and corporate lawyer focused on healthcare, retail and the consumer sectors, Mr. Lin was most recently based in HongKong. His experience entails IPOs, debt and equity financings and M&As for leading companies in Asia, the UnitedStates and Europe. Mr. Lin received a Bachelor of Sciences degree in Biological Sciences from the University of California at Davis and a Juris Doctor degree from The University of Chicago Law School.
As Hua's EVP and CFO, Mr. Lin's responsibilities will include corporate finance, business development and licensing / partnering efforts, as Hua moves forward with its novel Phase III GKA diabetes treatment drug.
Hua Medicine successfully completed its proof-of-concept study Phase II clinical trial for Dorzagliatin (HMS5552), a novel First-in-Class Glucokinase PositiveAllosteric Modulator (PAM) for the treatment of diabetes in 258 patients in 22leading hospital centers across China in 2016 [News release Hua Medicine October 2016]. In China, the company has initiated the NDA enabling process and has started two Phase III clinical trials targeting on drug naive and metformin treated T2Dpatients in China led by Professor Dalong Zhu, President-elect of ChinaDiabetes Society (CDS), and Professor Wenying Yang, Former President of CDS, with80 clinical sites located throughout China participating.
"We are very pleased to have George lead our finance and business development efforts at Hua Medicine as we advance our innovative diabetes medicine for patients in China and worldwide.” said Dr. Li Chen, CEO of Hua Medicine. "Today, diabetes is a global pandemic affecting, according to the WHO, over 422 M people worldwide and 120 M in China alone. The prevalence of T2D is 14.7% in the China Han population, 10% in the China Muslim population, and 9.4% in the U.S. as a whole. The progressive nature of the disease is attributable, in part, to the limited effectiveness of existing medications and untreated dysfunction of glucose sensor protein GK. HuaMedicine’s GK PAM demonstrated its potential to modulate the damaged function of GK in T2D patients and to regain the control of glucose homoeostasis, a novel concept to stop the progression of T2D."
About Hua Medicine
Hua is a leading, clinical stage innovative drug development company in China focused on novel therapies for the treatment of diabetes. Founded by an experienced group of entrepreneurs and international investment firms, Hua advanced a first-in-class oral drug for the treatment of Type 2 Diabetes into NDA enabling stage and started 2 Phase IIItrials in China. The Company also has initiated product life-cycle management studies of this novel diabetes drug, and advanced the knowledge in personalized diabetes care. Hua's strategy is to leverage the cost-efficient and high-quality drug development capabilities available in China, while working very closely with disease experts and regulatory agencies in China and rest of the World to advance diabetes care solutions for global patients. For more information: www.huamedicine.com.
华领医药/报道
本文由华领医药团队整理，欢迎分享。转载请于文章开头注明 “本文来源于华领医药微信公众号（ID：huamedicine )”
